Surfaxin

http://kinedu.getmyip.com/tutihug/
surfaxin

Discovery Laboratories, Inc. (Nasdaq:DSCO) announces the publication of results from its Phase 2 clinical trial of Surfaxin(r) for the prevention and treatment of Bronchopulmonary
Lung wash with Surfaxin, of individual lung segments using a bronchoscope compared to usual care alone consisting primarily of assisted (mechanical) ventilation in patients with
Surfaxin Treatment for Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight (VLBW) Infants.
To print: Select File and then Print from your browser's menu-----Title: Surfaxin Effective In
that it has achieved technical success in addressing the key remaining requirements identified by the U.S. Food and Drug Administration (FDA) to gain marketing approval of Surfaxin
Free Online Library: SURFAXIN GETS ORPHAN DRUG DESIGNATION FROM EMEA. by "Worldwide Biotech"; Biotechnology industry Business
Discovery Labs Reports Progress in Responding to Surfaxin FDA Approvable Letter Warrington, PA - August 6, 2008, -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announces that it has
Surfaxin (lucinactant) is a new drug in development for the treatment of Respiratory Distress Syndrome. Surfaxin information includes news, clinical trial results and side effects.
Surfaxin. Discovery Labs' first product based on KL4 technology is SURFAXIN ® (lucinactant), a liquid instillate formulation targeting Respiratory Distress Syndrome
Affordable web hosting services and dedicated hosting from ValueWeb. Find the right web hosting plan to meet your business and ecommerce needs.